Cytokeratin19 expression discriminates papillary thyroid carcinoma from other thyroid lesions and predicts its aggressive behavior

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Isic Dencic, Tijana ^a   Cvejic, Dubravka ^a   Paunovic, Ivan ^b   Tatic, Svetislav ^a   Havelka, Marija ^a   Savin, Svetlana ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Cytokeratin19; Diagnosis; Immunohistochemistry; Prognosis; Thyroid carcinoma

Indexed keywords

CYTOKERATIN 19;

ADULT; AGED; ANAPLASTIC THYROID CANCER; ARTICLE; CANCER PROGNOSIS; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLICULAR CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA;

ADENOMA; ADOLESCENT; ADULT; AGED; CARCINOMA, PAPILLARY, FOLLICULAR; CHILD; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-19; MALE; MIDDLE AGED; NEOPLASM STAGING; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84871437750     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0362-1     Document Type: Article

References (32)

1. DeLellis RA, Lloyd RY, Heitz PU, Eng C. Pathology and genetics of tumours of endocrine organs. In: DeLellis RA, Lloyd RY, Heitz PU, Eng C, editors. World Health Organization classification of tumors. Lyon: IARC Press, 2004. p. 50-66.
2. Treseler PA, Clark OH. Prognostic factors in thyroid carcinoma. Surg Oncol Clin N Am. 1997;6(3):555-98.
3. Brierley JD, Panzarella T, Tsang RW, Gospodarowicz MK, O'Sullivan B. A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example. Cancer. 1997;79(12):2414-23.
4. Sanders LE, Cady B. Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. Arch Surg. 1998;133(4):419-25.
5. Dean DS, Hay ID. Prognostic indicators in differentiated thyroid carcinoma. Cancer Control. 2000;7(3):229-39.
6. Fischer S, Asa SL. Application of immunohistochemistry to thyroid neoplasms. Arch Pathol Lab Med. 2008;132(3):359-72.
7. Serra S, Asa SL. Controversies in thyroid pathology: the diagnosis of follicular neoplasms. Endocr Pathol. 2008;19(3):156-65.
8. Barut F, OnakKandemir N, Bektas S, Bahadir B, Keser S, Ozdamar SO. Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19. Endocr Pathol. 2010;21(2):80-9.
9. Sethi K, Sarkar S, Das S, Mohanty B, Mandal M. Biomarkers for the diagnosis of thyroid cancer. J Exp Ther Oncol. 2010;8(4):341-52.
10. Cheng S, Serra S, Mercado M, Ezzat S, Asa SL. A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior. Clin Cancer Res. 2011;17(8):2385-94.
11. Bártek J, Bártková J, Taylor-Papadimitriou J, Rejthar A, Kovarík J, Lukás Z, Vojtsek B. Differential expression of keratin 19 in normal human epithelial tissues revealed by monospecific monoclonal antibodies. Histochem J. 1986;18(10):565-75.
12. Kwaspen FH, Smedts FM, Broos A, Bulten H, Debie WM, Ramaekers FC. Reproducible and highly sensitive detection of the broad spectrum epithelial marker keratin 19 in routine cancer diagnosis. Histopathology. 1997;31(6):503-16.
13. Michel M, Török N, Godbout MJ, Lussier M, Gaudreau P, Royal A, Germain L. Keratin 19 as a biochemical marker of skin stem cells in vivo and in vitro: keratin 19 expressing cells are differentially localized in function of anatomic sites, and their number varies with donor age and culture stage. J Cell Sci. 1996;109(Pt 5):1017-28.
14. Jain R, Fischer S, Serra S, Chetty R. The use of Cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas, gastrointestinal tract, and liver. Appl Immunohistochem Mol Morphol. 2010;18(1):9-15.
15. Sethi K, Sarkar S, Das S, Rajput S, Mazumder A, Roy B, Patra S, Mohanty B, El-Naggar AK, Mandal M. Expressions of CK-19, NF-kappaB, E-cadherin, beta-catenin and EGFR as diagnostic and prognostic markers by immunohistochemical analysis in thyroid carcinoma. J Exp Ther Oncol. 2011;9(3):187-99.
16. Asa SL. The role of immunohistochemical markers in the diagnosis of follicular-patterned lesions of the thyroid. Endocr Pathol. 2005;16(4):295-309.
17. de Matos PS, Ferreira AP, de Oliveira F, Assumpcao LVM, Matze K, Ward LS. Usefulness of HBME-1, Cytokeratin 19 and Galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology. 2005;47:391-401.
18. Park YJ, Kwak SH, Kim DC, Kim H, Choe G, Park do J, Jang HC, Park SH, Cho BY, Park SY. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules. J Korean Med Sci. 2007;22(4):621-8.
19. Zhu X, Sun T, Lu H, Zhou X, Lu Y, Cai X, Zhu X. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma. J Clin Pathol. 2010;63(9):786-9.
20. Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol. 2001;14:338-42.
21. Sahoo S, Hoda SA, Rosai J, DeLellis RA. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution. Am J Clin Pathol. 2001;116(5):635-6.
22. Shin E, Chung WY, Yang WI, Park CS, Hong SW. RET/PTC and CK19 expression in papillary thyroid carcinoma and its clinicopathologic correlation. J Korean Med Sci. 2005;20(1):98-104.
23. Suo Z, Holm R, Nesland JM. Squamous cell carcinomas. An immunohistochemical study of cytokeratins and involucrin in primary and metastatic tumours. Histopathology. 1993;23(1):45-54.
24. Lam KY, Lo CY, Liu MC. Primary squamous cell carcinoma of the thyroid gland: an entity with aggressive clinical behaviour and distinctive cytokeratin expression profiles. Histopathology. 2001;39(3):279-86.
25. Rosai J, Carcangiu ML, DeLellis RA. Tumors of the thyroid gland. In: Rosai J, Carcangiu ML, DeLellis RA, editors. Atlas of Tumor Pathology, Third Series, Fascicle 5. Washington, DC: Armed Forces Institute of Pathology; 1992. p. 65-121.
26. Hermanek P, Sobin LH, editors. UICC: TNM classification of malignant tumors. 4th ed, 2nd revision. Berlin: Springer; 1992.
27. Laco J, Ryska A, Cáp J, Celakovský P. Expression of galectin-3, cytokeratin 19, neural cell adhesion molecule and E-cadhedrin in certain variants of papillary thyroid carcinoma. Cesk Patol. 2008;44(4):103-7.
28. Vriens MR, Schreinemakers JM, Suh I, Guerrero MA, Clark OH. Diagnostic markers and prognostic factors in thyroid cancer. Future Oncol. 2009;5(8):1283-93.
29. Prasad M, Pellegata N, Huang Y, Nagaraja H, de la Chapelle A, Kloos R. Galectin-3, fibronectin-1, CITED-1, HBME-1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid Tumors. Mod Pathol. 2005;18:48-57.
30. Nakamura N, Erickson LA, Jin L, Kajita S, Zhang H, Qian X, Rumilla K, Lloyd RV. Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma. EndocrPathol. 2006;17(3):213-23.
31. Uenishi T, Kubo S, Yamamoto T, Shuto T, Ogawa M, Tanaka H, Tanaka S, Kaneda K, Hirohashi K. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci. 2003;94(10):851-7.
32. Kim H, Choi GH, Na DC, Ahn EY, Kim GI, Lee JE, Cho JY, Yoo JE, Choi JS, Park YN. Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 19 expression and a poor prognosis. Hepatology. 2011;54(5):1707-17.